Resource Summary Report

Generated by NIF on Aug 3, 2026

HuCC-T1

RRID:CVCL_0324
Type: Cell Line

Proper Citation

RRID:CVCL_0324

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0324

Proper Citation: RRID:CVCL_0324

Description: Cell line HuCC-T1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Intrahepatic cholangiocarcinoma

Defining Citation: PMID:2544546, PMID:9290701, PMID:20164919, PMID:20215515, PMID:21451941, PMID:21687941, PMID:22460905, PMID:25877200, PMID:26956050, PMID:27231123, PMID:27397505, PMID:30894373, PMID:31068700, PMID:31077409, PMID:31395879, PMID:32899426, PMID:35640676, PMID:35839778, PMID:39026794

Comments: Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: Biliary tract cancer cell line atlas.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HuCC-T1

Synonyms: HuCCT-1, HUCCT-1, HUCC-T1, HUCCT1, HuCCT1, HuccT1

Cross References: BTO:BTO_0003911, CLO:CLO_0050009, MCCL:MCC:0000217, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN01821687, BioSample:SAMN03470954, BioSample:SAMN03471627, BioSample:SAMN10987837, cancercelllines:CVCL_0324, CCRID:5301HUM-KCB21005YJ, Cell_Model_Passport:SIDM00587, ChEMBL-Cells:CHEMBL3307409, ChEMBL-Targets:CHEMBL614581, CLS:300469, Cosmic:907069, Cosmic:1122350,

Cosmic:1571782, Cosmic:2009540, Cosmic:2629288, Cosmic:2674063, Cosmic-CLP:907069, DepMap:ACH-000976, EGA:EGAS00001000978, FANTOM5_SSTAR:10432-106D9, GDSC:907069, GEO:GSM827224, GEO:GSM887144, GEO:GSM888216, GEO:GSM1669917, IARC_TP53:21387, JCRB:JCRB0425, KCB:KCB 202105YJ, LiGeA:CCLE_833, LINCS_LDP:LCL-1788, PharmacoDB:HuCCT1_635_2019, PRIDE:PXD030304, PRIDE:PXD033685, Progenetix:CVCL_0324, PubChem_Cell_line:CVCL_0324, RCB:RCB1960, TKG:TKG 0389, Wikidata:Q54896725

ID: CVCL_0324

Record Creation Time: 20220427T220620+0000

Record Last Update: 20260802T001920+0000

Ratings and Alerts

No rating or validation information has been found for HuCC-T1.

No alerts have been found for HuCC-T1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 365 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Taguchi D, et al. (2025) Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866. International journal of molecular sciences, 26(3).

Zhao CH, et al. (2025) Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma. World journal of gastrointestinal oncology, 17(4), 103776.

Luo G, et al. (2025) Platelets promote metastasis of intrahepatic cholangiocarcinoma through activation of TGF-?/Smad2 pathway. Biochimica et biophysica acta. Molecular basis of disease, 1871(4), 167734.

Inthanachai T, et al. (2025) Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study. Journal for immunotherapy of cancer, 13(1).

Yuan WC, et al. (2025) HBO1 functions as an epigenetic barrier to hepatocyte plasticity and reprogramming during liver injury. Cell stem cell, 32(6), 990.

Chen T, et al. (2024) S100A6 drives lymphatic metastasis of liver cancer via activation of the RAGE/NF-kB/VEGF-D pathway. Cancer letters, 587, 216709.

Myint KZ, et al. (2024) Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals (Basel, Switzerland), 17(2).

Bekric D, et al. (2024) The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. PloS one, 19(4), e0302050.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Alva-Ruiz R, et al. (2024) YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. FEBS open bio, 14(11), 1873.

Cai TT, et al. (2024) Septin 9 expression regulates 'don't eat me' signals and identifies an immune-epithelial class of intrahepatic cholangiocarcinoma. Molecular oncology, 18(10), 2369.

Noronha KJ, et al. (2024) NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion. Molecular cancer research : MCR, 22(10), 973.

Toshida K, et al. (2023) Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma. Cancer science, 114(3), 937.

Kim J, et al. (2023) Targeting AXL Using the AVB-500 Soluble Receptor and through Genetic Knockdown Inhibits Bile Duct Cancer Growth and Metastasis. Cancers, 15(6).

Liu S, et al. (2023) ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in Cholangiocarcinoma. BMC cancer, 23(1), 444.

Shiode Y, et al. (2023) TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF-?B-inducing kinase-mediated hepatocyte transdifferentiation. Hepatology (Baltimore, Md.), 77(2), 395.

Zhang Y, et al. (2023) Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2. Oncology research, 31(3), 317.

Chen J, et al. (2023) SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial-mesenchymal transition and mitochondrial function maintenance. Cancer medicine, 12(1), 459.

Gao CQ, et al. (2023) Serine/threonine kinase TBK1 promotes cholangiocarcinoma progression via direct regulation of ?-catenin. Oncogene, 42(18), 1492.

Deng M, et al. (2023) Proteogenomic characterization of cholangiocarcinoma. Hepatology (Baltimore, Md.), 77(2), 411.